```html

Thrombotic Thrombocytopenic Purpura (TTP) – A Complete Patient‑Friendly Guide

Overview

Thrombotic thrombocytopenic purpura (TTP) is a rare, life‑threatening blood disorder characterized by the formation of small blood clots (thrombi) in the microvasculature throughout the body. These clots consume platelets, leading to a low platelet count (thrombocytopenia), and they also cause mechanical damage to red blood cells, resulting in hemolytic anemia. When the clotting occurs in vital organs—most commonly the brain, kidneys, and heart—patients can develop neurologic deficits, renal failure, or cardiac ischemia.

There are two major forms:

• Acquired (immune) TTP: Accounts for ~90 % of cases and is caused by auto‑antibodies that inhibit the enzyme ADAMTS13.
• Hereditary (congenital) TTP: A rare autosomal‑recessive condition caused by mutations in the ADAMTS13 gene.

Who it affects: Although TTP can occur at any age, the acquired form is most common in adults (median age 40‑45 years) and occurs three‑times more often in women than men. Congenital TTP typically presents in infancy or early childhood.

Prevalence: The incidence of acquired TTP in the United States is estimated at 3–4 cases per million people per year, translating to roughly 10 000 new cases worldwide annually. Mortality historically exceeded 90 % before the introduction of plasma exchange, but modern therapy now yields a survival rate of 80‑90 % [Mayo Clinic].

Symptoms

TTP usually presents with a rapid onset of symptoms that can affect multiple organ systems. The classic “pentad” (five features) is seen in only a minority of patients, but awareness of the full symptom spectrum helps prompt diagnosis.

Hematologic

• Thrombocytopenia – Bruising, petechiae (tiny red spots), or spontaneous bleeding from gums, nose, or gastrointestinal tract.
• Microangiopathic hemolytic anemia (MAHA) – Fatigue, pallor, dark urine (due to hemoglobin), and elevated lactate dehydrogenase (LDH).

Neurologic

• Headache or migraine‑type pain
• Confusion, agitation, or altered mental status
• Seizures (up to 15 % of cases)
• Focal deficits such as weakness, vision changes, or speech difficulty

Renal

• Decreased urine output or “frothy” urine from proteinuria
• Flank pain or hematuria
• Acute kidney injury (creatinine rise)

Cardiovascular

• Chest pain or angina‑like discomfort
• Palpitations; rare cases of myocardial infarction due to microvascular thrombosis.

Other systemic signs

• Fever (often low‑grade)
• Generalized malaise or myalgias
• Jaundice from hemolysis

Because the presentation can be nonspecific, any combination of a low platelet count with signs of hemolysis (elevated LDH, indirect bilirubin, schistocytes on blood smear) should raise suspicion for TTP.

Causes and Risk Factors

Pathophysiology

In >95 % of acquired TTP, auto‑antibodies neutralize ADAMTS13, a metalloprotease that cleaves ultra‑large von Willebrand factor (vWF) multimers. Without ADAMTS13, vWF multimers remain unusually long, causing platelets to bind and aggregate in the small‑vessel endothelium, forming thrombi.

Triggers for Acquired TTP

• Recent infections (especially viral such as HIV, influenza, COVID‑19)
• Pregnancy or the postpartum period (particularly the third trimester)
• Medications: quinine, ticlopidine, clopidogrel, cyclosporine, certain antiplatelet agents, and some antibiotics
• Autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis)
• Malignancies, especially solid tumors or hematologic cancers

Risk Factors for Hereditary TTP

• Consanguineous parents or family history of early‑onset TTP
• Genetic mutations in ADAMTS13 (over 150 known variants)

Population‑level Risk

Women of child‑bearing age have the highest incidence, largely because of the pregnancy‑related trigger. African‑American individuals appear to have a slightly higher reported incidence, though data are limited.

Diagnosis

Rapid diagnosis is essential; treatment should begin before confirmatory test results if clinical suspicion is high.

Initial Laboratory Evaluation

• Complete blood count (CBC) – low platelets, anemia.
• Peripheral blood smear – presence of schistocytes (fragmented red cells).
• LDH – markedly elevated due to hemolysis.
• Haptoglobin – decreased or undetectable.
• Indirect bilirubin – elevated.
• Creatinine – assess renal involvement.
• Coagulation panel (PT, aPTT, fibrinogen) – typically normal, which helps differentiate from disseminated intravascular coagulation (DIC).

Specific ADAMTS13 Testing

Quantitative ADAMTS13 activity < 10 % is diagnostic of TTP. Two assay types are used:

1. Fluorescence resonance energy transfer (FRET) assays – rapid, but may be unavailable in community hospitals.
2. Immunoblot or ELISA for anti‑ADAMTS13 antibodies – confirms acquired form.

Because these tests may take days, clinicians rely on a clinical scoring system (the PLASMIC score) to estimate pre‑test probability.

PLASMIC Score (0–7 points)

Variable	Point
Platelet count < 30 ×10⁹/L	1
Hemolysis (elevated LDH, undetectable haptoglobin)	1
No active cancer	1
No solid organ transplant	1
Mean corpuscular volume < 90 fL	1
INR < 1.5	1
Creatinine < 2.0 mg/dL	1

A score of 6–7 = high risk; start plasma exchange immediately.

Imaging (as needed)

• CT or MRI brain if neurologic deficits are present – to rule out stroke.
• Renal ultrasound for acute kidney injury.
• Echocardiogram if cardiac involvement is suspected.

Treatment Options

Therapy is three‑pronged: (1) replace missing ADAMTS13 activity, (2) suppress the auto‑antibody, and (3) support organ function.

First‑Line: Therapeutic Plasma Exchange (TPE)

• Daily exchange of 1–1.5 plasma volumes with fresh frozen plasma (FFP) or solvent/detergent‑treated plasma.
• Removes inhibitory antibodies and supplies functional ADAMTS13.
• Median time to platelet recovery: 5–7 days.

Immunosuppression

• Corticosteroids – Methylprednisolone 1 mg/kg IV daily, then oral taper.
• Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks; reduces relapse risk (up to 50 % lower relapses) [NEJM, 2017].
• Emerging agents:
  • Caplacizumab – anti‑vWF nanobody that blocks platelet‑vWF interaction. In the HERCULES trial, it shortened time to platelet normalization by 2.7 days and reduced mortality to 2 % [Lancet, 2019].
  • Recombinant ADAMTS13 (rADAMTS13) – FDA‑approved for congenital TTP (2023); being studied for acquired disease.

Supportive Care

• Transfusion of red blood cells for symptomatic anemia.
• Avoid platelet transfusions unless life‑threatening bleeding, as they may worsen thrombosis.
• Renal replacement therapy if severe AKI.
• Antihypertensives for blood‑pressure control.

Long‑Term Management

After acute remission, many patients require maintenance immunosuppression (low‑dose steroids, rituximab re‑dosing, or mycophenolate). Regular monitoring of ADAMTS13 activity every 3–6 months helps predict relapse.

Living with Thrombotic Thrombocytopenic Purpura

Follow‑up Schedule

• First month: weekly CBC, LDH, and renal panel.
• Months 2‑6: bi‑weekly labs; assess ADAMTS13 activity.
• After 6 months: every 3 months if stable; sooner if symptoms recur.

Practical Lifestyle Tips

• Hydration – Aim for ≥2 L/day to support renal clearance.
• Nutrition – Balanced diet rich in iron, folate, and vitamin B12 to aid erythropoiesis.
• Medication adherence – Never skip steroids or rituximab doses; set reminders.
• Infection prevention – Hand hygiene, timely vaccinations (influenza, COVID‑19, pneumococcal). Avoid live vaccines while on high‑dose immunosuppression.
• Pain/Headache management – Use acetaminophen; limit NSAIDs (increase bleeding risk).
• Pregnancy planning – Discuss with a hematologist‑obstetrician; prophylactic plasma exchange may be needed during pregnancy.

Psychosocial Support

Living with a rare, potentially relapsing disease can be stressful. Seek counseling, join support groups (e.g., TTP Foundation), and involve family in care planning.

Prevention

Because most cases are immune‑mediated, absolute prevention is impossible, but risk can be reduced:

• Prompt treatment of infections; consider prophylactic antivirals for known triggers (e.g., HIV).
• Review medication list with a pharmacist; avoid known precipitants such as quinine.
• During pregnancy, close hematologic monitoring and early involvement of a specialist.
• For hereditary TTP, early diagnosis (often via family screening) allows prophylactic plasma infusions to prevent first episode.

Complications

If untreated or inadequately treated, TTP can lead to:

• Permanent neurologic damage – stroke, cognitive impairment.
• End‑stage renal disease – requiring dialysis.
• Cardiac injury – myocardial infarction, heart failure.
• Severe hemorrhage – intracranial or gastrointestinal.
• Relapse – up to 30‑50 % of patients experience at least one recurrence, especially within the first year.
• Treatment‑related adverse effects – catheter‑related infections, allergic reactions to plasma, steroid‑induced hyperglycemia, or rituximab‑related hepatitis reactivation.

When to Seek Emergency Care

Key Take‑aways

• TTP is a medical emergency; early plasma exchange saves lives.
• A low PLASMIC score and ADAMTS13 activity <10 % confirm the diagnosis.
• Combination therapy with plasma exchange, steroids, and rituximab (or caplacizumab) is the modern standard.
• Continuous follow‑up and ADAMTS13 monitoring reduce relapse risk.
• Patients should stay vigilant for neurologic or bleeding symptoms and seek emergency care without delay.

References:

1. Mayo Clinic. Thrombotic thrombocytopenic purpura (TTP). https://www.mayoclinic.org
2. CDC. Rare Bleeding Disorders. https://www.cdc.gov
3. Joly BS, et al. Caplacizumab for Acquired TTP. The Lancet. 2019;393:1652‑1661.
4. National Institutes of Health (NIH). TTP Clinical Guidelines. https://clinicalinfo.hhs.gov
5. World Health Organization. WHO Model List of Essential Medicines – plasma products. https://www.who.int
6. Wobma C, et al. Rituximab in TTP. New England Journal of Medicine. 2017;376:109‑118.

```